Cargando…
Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules
BACKGROUND: The tablet formulation of ritonavir-boosted lopinavir (LPV/r; Kaletra(®)) has many advantages over the soft gel capsule (SGC) formulation, including lower pill count, no refrigeration requirement, and no dietary restrictions. These advantages may help improve patient compliance and there...
Autores principales: | Schrader, Shannon, Chuck, Susan K, Rahn, Laurie W, Parekh, Paras, Emrich, Katherine G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563011/ https://www.ncbi.nlm.nih.gov/pubmed/18799008 http://dx.doi.org/10.1186/1742-6405-5-21 |
Ejemplares similares
-
Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients
por: Ofotokun, Ighovwerha, et al.
Publicado: (2009) -
The Palatability of Lopinavir and Ritonavir Delivered by an Innovative Freeze-Dried Fast-Dissolving Tablet Formulation
por: Pittman, David W., et al.
Publicado: (2018) -
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023) -
Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients
por: Eljaaly, Khalid, et al.
Publicado: (2020) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)